Important: Therapy notes
MHRA advice: Ivabradine: carefully monitor for bradycardia (December 2014) (www.gov.uk)
MHRA advice: Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects (December 2014) (www.gov.uk)
Important: Formulation and dosage details
Formulation:
Tablets 5mg, 7·5mg
Dosage:
Angina: (for people in sinus rhythm) initially 5mg twice daily, increased if necessary after 3 to 4 weeks to 7·5mg twice daily (if not tolerated reduce dose to 2·5 to 5mg twice daily); older people initially 2·5mg twice daily.
Chronic heart failure NYHA II to IV with systolic dysfunction, in patients in sinus rhythm whose resting heart rate remains at 75 or more beats per minute despite optimal standard therapy: (specialist use only) initially 5mg twice daily, increased if necessary after 2 weeks to 7·5mg twice daily (if not tolerated reduce dose to 2·5mg twice daily). Ventricular rate at rest should not be allowed to fall below 50 beats per minute.